Life Science
for the ExPERT.
Through its Life Sciences business, MaxCyte leverages its Flow Electroporation® Technology to enable its biopharmaceutical partners to advance the development of innovative medicines, particularly in cell therapy. We call this line of products our ExPERT platform.
![]() |
Explore the ExPERT Platform |
Previously unfeasible
cell-engineering
applications.
Our cell-engineering platform harnesses the power of the cell to accelerate the development of small molecule drugs, biologics, vaccines and cell and gene therapies to address a wide array of acute and chronic disease indications.
![]() |
MaxCyte Inc. Rings the Nasdaq Stock Market Closing Bell
MaxCyte, Inc. (Nasdaq: MXCT),visits the Nasdaq MarketSite in Times Square. Doug Doerfler, President, Chief Executive Officer and Founder, rings the Closing Bell.